Napredna pretraga

Pregled bibliografske jedinice broj: 464634

Body Mass Index and Diffuse Large B Cell Lymphoma


Marijić, Blažen; Pećanić, Sanja; Licul, Vanja; Štifter, Sanja; Jonjić, Nives; Valković, Toni; Petranović, Duška; Načinović Duletić, Antica
Body Mass Index and Diffuse Large B Cell Lymphoma // BIT"s Life Science 2nd Annual World Cancer Congress, Beijing 2009, Abstract book
Beijing, 2009. str. 524-524 (poster, nije recenziran, sažetak, ostalo)


Naslov
Body Mass Index and Diffuse Large B Cell Lymphoma

Autori
Marijić, Blažen ; Pećanić, Sanja ; Licul, Vanja ; Štifter, Sanja ; Jonjić, Nives ; Valković, Toni ; Petranović, Duška ; Načinović Duletić, Antica

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
BIT"s Life Science 2nd Annual World Cancer Congress, Beijing 2009, Abstract book / - Beijing, 2009, 524-524

Skup
BITs Life Science 2nd Annual World Cancer Congress, Beijing 2009

Mjesto i datum
Peking, Kina, 22-25. 06. 2009

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
BMI; DLBCL

Sažetak
Background: Biological plausibility and evidence from case series indicate that an increased body mass index (BMI) could be a risk factor for non Hodgkin lymphoma. In a population-based case-control study, obesity was associated with elevated odds ratios (ORs) for non-Hodgkin lymphoma (NHL), and the two major subtypes, diffuse large cell (DLCL) and follicular lymphoma (FL). There was need to find if BMI is correlating with response to therapy. The aim of this study was to analyze the association between body mass index, response to therapy in patient with DLBC. Also, we wanted investigate possible clinical usefulness of body mass index as prognostic parameter for treatment response in patients with this disease. Methods: This analysis included 94 patients with DLBCL, 46 men and 48 women with middle age of 66 years (18-87). Patients had clinical stage (CS) from I to IV according to Ann Arbor classification. We calculated BMI in the start of therapy and middle value was 26, 46 kg/m2 (18-35, 2). Patient received standard protocol for aggressive lymphomas (CHOP-R/CHOP protocol). On evaluation of disease, 43 patients were in complete remission (CR), 24 patients were in partial remission, and 29 were with progression of the disease. Also, in our study we included international prognostic index (IPI) with values from 0 to 5, Eastern Oncology Cooperative Group (EOCG) performance status with values from 0 to 4 and “B symptoms of disease (fever, night sweats, and weight loss). All those parameters were statistically compared with BMI. Results: No significant association was reported between BMI and response to therapy (p=0, 543), BMI and IPI (p= 0, 712), BMI and EOCG (p= 0, 835), BMI and CS (p=0, 996), BMI and B symptoms of disease (p=0, 356). Conclussion: According to this analysis it appears that BMI could not provide useful prognostic information and predict effects of therapy, but those are preeliminar results and we hope that in future investigations we will establish our theory.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekt / tema
062-1081872-0091 - Angiogeneza u agresivnih ne-Hodgkinovih limfoma (Antica Duletić-Načinović, )

Ustanove
Medicinski fakultet, Rijeka